28871-91-2

Basic information

• Product Name: (3aR,4S,7R,7aS)-rel-hexahydro-4,7-Epoxy-1H-isoindole-1,3(2H)-dione (Relative stereocheMistry)
• Synonyms: (3aR,4S,7R,7aS)-rel-hexahydro-4,7-Epoxy-1H-isoindole-1,3(2H)-dione (Relative stereocheMistry)
• CAS NO: 28871-91-2
• Molecular Formula: C8H9NO3
• Molecular Weight: 167.16196
• Mol File: 28871-91-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 395°Cat760mmHg
• Flash Point: 192.7°C
• Appearance: /
• Density: 1.398g/cm³
• Vapor Pressure: 1.89E-06mmHg at 25°C
• Refractive Index: 1.552
• CAS DataBase Reference: (3aR,4S,7R,7aS)-rel-hexahydro-4,7-Epoxy-1H-isoindole-1,3(2H)-dione (Relative stereocheMistry)(CAS DataBase Reference)
• NIST Chemistry Reference: (3aR,4S,7R,7aS)-rel-hexahydro-4,7-Epoxy-1H-isoindole-1,3(2H)-dione (Relative stereocheMistry)(28871-91-2)
• EPA Substance Registry System: (3aR,4S,7R,7aS)-rel-hexahydro-4,7-Epoxy-1H-isoindole-1,3(2H)-dione (Relative stereocheMistry)(28871-91-2)

Safety Data

• Hazardous Substances Data: 28871-91-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H9NO3/c10-7-5-3-1-2-4(12-3)6(5)8(11)9-7/h3-6H,1-2H2,(H,9,10,11)/t3-,4+,5-,6+

Upstream product

• 28874-46-6 endothall 
• 19878-26-3 (3aR,4R,7S,7aS)-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione 
• 57-13-6 urea 
• 29745-04-8 norcantharidin 
• 6253-28-7 exo-7-oxabicyclo[2.2.1]hept-4-ene-2,3-dicarboximide 

Downstream Products

• 2779-48-8 Exo-3,6-endoxo-hexahydrophthalsaeure-N-trichlormethyl-mercapto-imid 
• 91645-06-6 N-butyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboximide 
• 94461-26-4 N-octyl-7-oxabicyclo(2.2.1)heptane-2,3-dicarboximide 
• 86844-85-1 (1S,2R,6S,7R)-4-[(E)-(3-Phenyl-acryloyl)]-10-oxa-4-aza-tricyclo[5.2.1.0^2,6]decane-3,5-dione 

Relevant articles and documents

NOVEL LIPOPHILIC N-SUBSTITUTED NORCANTHARIMIDE DERIVATIVES AND USE THEREOF

PROBLEM TO BE SOLVED: To provide novel N-substituted norcantharimide derivatives that exhibit excellent selective cytotoxicity to cancerous cells. SOLUTION: The N-substituted norcantharimide derivatives are represented by formula (I). EFFECT: The N-substituted norcantharimide derivatives are useful as lead compounds for producing pharmaceutical compositions for treating cancer, particularly leukemia. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPO&INPIT

Synthesis of novel lipophilic N-Substituted norcantharimide derivatives and evaluation of their anticancer activities

This research attempted to study the effect of lipophilicity on the anticancer activity of N-substituted norcantharimide derivatives. Twenty-three compounds were synthesized and their cytotoxicities against five human cancer cell lines studied. The lipophilicity of each derivative was altered by its substituent, an alkyl, alkyloxy, terpenyl or terpenyloxy group at the N-position of norcantharimide. Further, among all synthesized derivatives studied, the compounds N-farnesyloxy-7-oxabicyclo[2.2.1]heptane-2,3- dicarboximide (9), and N-farnesyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboximide (18), have shown the highest cytotoxicity, anti-proliferative and apoptotic effect against human liver carcinoma HepG2 cell lines, yet displayed no significant cytotoxic effect on normal murine embryonic liver BNL CL.2 cells. Their overall performance led us to believe that these two compounds might be potential candidates for anticancer drugs development.